See more : Columbia Care Inc. (CCHW.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Sandoz Group AG (SDZNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sandoz Group AG, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Hydro One Limited (H.TO) Income Statement Analysis – Financial Results
- Cohn Robbins Holdings Corp. Red (CRHC-WT) Income Statement Analysis – Financial Results
- Yellowstone Acquisition Company (YSAC) Income Statement Analysis – Financial Results
- TES Touch Embedded Solutions (Xiamen) Co., Ltd. (003019.SZ) Income Statement Analysis – Financial Results
- China Ludao Technology Company Limited (2023.HK) Income Statement Analysis – Financial Results
Sandoz Group AG (SDZNY)
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 9.98B | 8.86B | 8.79B | 9.04B |
| Cost of Revenue | 5.42B | 4.71B | 4.64B | 4.88B |
| Gross Profit | 4.56B | 4.15B | 4.15B | 4.16B |
| Gross Profit Ratio | 45.74% | 46.87% | 47.20% | 45.99% |
| Research & Development | 926.00M | 795.57M | 832.90M | 819.41M |
| General & Administrative | 0.00 | 22.50K | 0.00 | 0.00 |
| Selling & Marketing | 2.39B | 0.00 | 0.00 | 0.00 |
| SG&A | 2.39B | 22.50K | 1.94B | 2.00B |
| Other Expenses | 874.00M | 8.60M | 6.40M | 5.63M |
| Operating Expenses | 4.19B | 22.50K | 2.77B | 2.81B |
| Cost & Expenses | 9.60B | 22.50K | 7.41B | 7.69B |
| Interest Income | 31.00M | 7.64M | 4.57M | 2.82M |
| Interest Expense | 202.00M | 84.05M | 61.26M | 70.40M |
| Depreciation & Amortization | 525.00M | 437.42M | 447.08M | 650.46M |
| EBITDA | 857.00M | 1.68B | 1.83B | 1.99B |
| EBITDA Ratio | 8.59% | 0.00% | 20.77% | 22.03% |
| Operating Income | 375.00M | -22.50K | 1.38B | 1.34B |
| Operating Income Ratio | 3.76% | 0.00% | 15.69% | 14.83% |
| Total Other Income/Expenses | -245.00M | -137.00M | -179.20M | -677.68M |
| Income Before Tax | 130.00M | -22.50K | 1.20B | 662.66M |
| Income Before Tax Ratio | 1.30% | 0.00% | 13.65% | 7.33% |
| Income Tax Expense | 50.00M | 361.00 | 368.45M | 227.14M |
| Net Income | 77.00M | -22.86K | 830.15M | 433.64M |
| Net Income Ratio | 0.77% | 0.00% | 9.44% | 4.80% |
| EPS | 0.18 | 0.00 | 1.93 | 1.01 |
| EPS Diluted | 0.18 | 0.00 | 1.93 | 1.01 |
| Weighted Avg Shares Out | 429.90M | 431.00M | 431.00M | 431.00M |
| Weighted Avg Shares Out (Dil) | 431.20M | 431.00M | 431.00M | 431.00M |
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market
MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab injection) for all approved indications Dedicated retina sales and field reimbursement team integrated into Sandoz, ensuring seamless experience for providers and patients Basel, March 4, 2024 – Sandoz, the...
Sandoz enters $265 mln settlement agreement in U.S. price-fixing case
Swiss generic and biosimilar manufacturer Sandoz on Thursday said it had entered into a $265 million settlement agreement in a price-fixing case in the United States.
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Sandoz US to pay USD 265 million in exchange for full release of all claims by the class Resolves all federal antitrust damages for direct purchaser...
Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab
BENGALURU, India, Feb. 8, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced a five-year partnership with Sandoz AG ('Sandoz') which provides Sandoz the exclusive rights to...
Sandoz announces changes in the Board of Directors
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Graeme Pitkethly nominated as candidate for election to the Sandoz Board of Directors at the upcoming Annual General Meeting François-Xavier Roger announced to pursue a new...
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Tyruko® approved for all indications of reference medicine Tyruko® biosimilar to treat adults with highly active relapsing remitting multiple...
Sandoz to buy eye drug Cimerli in $170 million deal
Sandoz on Monday announced a deal to buy Cimerli, a biosimilar drug to treat vision impairment and loss, from Coherus BioSciences Inc. for $170 million.
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab-injection) for all approved indications Acquisition strengthens Sandoz ophthalmology portfolio Basel, January 22, 2024 – Sandoz, the global...
South Africa's Aspen Pharmacare to buy Sandoz's China business
Aspen Pharmacare will buy the Chinese business of Swiss group Sandoz , including commercialisation rights and intellectual property for some established products and those in the pipeline, for up to 92.6 million euros ($100.6 million), the South African company said...
Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve patient care
Basel, November 21, 2023 – Sandoz, the global leader in generic and biosimilar medicines, today announces the launch of Hyrimoz® (adalimumab) citrate-free high concentration formulation (HCF; 100 mg/mL) in Europe. The medicine will become available to patients progressively across European...
Source: https://incomestatements.info
Category: Stock Reports